# Efficacy of DNK333 in Patients With COPD and Cough

> **NCT01287325** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 28 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** DNK333 100 mg twice daily
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01287325
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-04
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2011-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01287325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01287325, "Efficacy of DNK333 in Patients With COPD and Cough". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01287325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*